Effectiveness of single-pill combination olmesartan/amlodipine/hydrochlorothiazide therapy in patients with apparent resistant hypertension

5 15

Cited 0 times in

Authors: Oh, Jaewon ; Kim, Wonho ; Kim, Gee-Hee ; Kim, Hack-Lyoung ; Park, Sang-Don ; Min, Kyung Wan ; Hyun, Dongkeun ; Hong, Jun Hwa ; Lim, Soo ; Bae, Ji-Hwan ; Shin, Jinho

MeSH: Adult ; Aged ; Amlodipine* / administration & dosage ; Amlodipine* / adverse effects ; Amlodipine* / therapeutic use ; Antihypertensive Agents* / administration & dosage ; Antihypertensive Agents* / adverse effects ; Antihypertensive Agents* / therapeutic use ; Blood Pressure* / drug effects ; Drug Combinations ; Drug Resistance ; Drug Therapy, Combination ; Female ; Humans ; Hydrochlorothiazide* / administration & dosage ; Hydrochlorothiazide* / adverse effects ; Hydrochlorothiazide* / therapeutic use ; Hypertension* / diagnosis ; Hypertension* / drug therapy ; Hypertension* / physiopathology ; Imidazoles* / administration & dosage ; Imidazoles* / therapeutic use ; Male ; Middle Aged ; Olmesartan Medoxomil ; Tetrazoles* / administration & dosage ; Tetrazoles* / therapeutic use ; Treatment Outcome

Abstract: This pioneering study investigated the real-life effectiveness of single-pill combination (SPC) antihypertensive therapy in patients with uncontrolled blood pressure (BP) and cardiovascular risk factors. After treatment with olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide for 24 weeks, adults with apparent resistant hypertension had significantly reduced systolic BP and approximately 80% achieved target BP. SPC therapy may improve adherence in patients with pseudo-resistant hypertension and is a potentially effective treatment for resistant hypertension.